Laura D. Zambrano, Margaret M. Newhams, Regina M Simeone, Amanda B. Payne, Michael Wu, Amber O Orzel-Lockwood, N. Halasa, Jemima M Calixte, Pia S Pannaraj, K. Mongkolrattanothai, J. Boom, Leila C. Sahni, S. Kamidani, K. Chiotos, M. Cameron, A. Maddux, K. Irby, J. Schuster, E. Mack, Austin Biggs, B. Coates, Kelly N. Michelson, Katherine E Bline, Ryan A Nofziger, Hillary R Crandall, Charlotte V Hobbs, S. Gertz, Sabrina M. Heidemann, T. Bradford, Tracie C Walker, S. Schwartz, M. Staat, Samina S Bhumbra, J. Hume, Michele Kong, M. Stockwell, Thomas J Connors, M. Cullimore, H. Flori, Emily R Levy, N. Cvijanovich, M. Zinter, Mia Maamari, Cindy Bowens, Danielle M. Zerr, J. Guzman-Cottrill, Ivan Gonzalez, Angela P Campbell, Adrienne G Randolph, M. Murdock, Heather Kelley, Candice Colston, Ronald C. Sanders, Laura Miron, M. Yates, Ashlyn Madding, Alexa Dixon, Michael Henne, Kathleen Sun, Jazmin Baez Maidana, Natalie Triester, Jaycee Jumarang, Daniel Hakimi, Kennis-Grace Mrotek, Liria Muriscot Niell, Natasha Baig, E
{"title":"2021-2023 年美国原始单价 mRNA 疫苗在预防 COVID-19 Omicron 相关儿童和青少年住院治疗方面的效力持续时间","authors":"Laura D. Zambrano, Margaret M. Newhams, Regina M Simeone, Amanda B. Payne, Michael Wu, Amber O Orzel-Lockwood, N. Halasa, Jemima M Calixte, Pia S Pannaraj, K. Mongkolrattanothai, J. Boom, Leila C. Sahni, S. Kamidani, K. Chiotos, M. Cameron, A. Maddux, K. Irby, J. Schuster, E. Mack, Austin Biggs, B. Coates, Kelly N. Michelson, Katherine E Bline, Ryan A Nofziger, Hillary R Crandall, Charlotte V Hobbs, S. Gertz, Sabrina M. Heidemann, T. Bradford, Tracie C Walker, S. Schwartz, M. Staat, Samina S Bhumbra, J. Hume, Michele Kong, M. Stockwell, Thomas J Connors, M. Cullimore, H. Flori, Emily R Levy, N. Cvijanovich, M. Zinter, Mia Maamari, Cindy Bowens, Danielle M. Zerr, J. Guzman-Cottrill, Ivan Gonzalez, Angela P Campbell, Adrienne G Randolph, M. Murdock, Heather Kelley, Candice Colston, Ronald C. Sanders, Laura Miron, M. Yates, Ashlyn Madding, Alexa Dixon, Michael Henne, Kathleen Sun, Jazmin Baez Maidana, Natalie Triester, Jaycee Jumarang, Daniel Hakimi, Kennis-Grace Mrotek, Liria Muriscot Niell, Natasha Baig, E","doi":"10.15585/mmwr.mm7315a2","DOIUrl":null,"url":null,"abstract":"Pediatric COVID-19 vaccination is effective in preventing COVID-19-related hospitalization, but duration of protection of the original monovalent vaccine during SARS-CoV-2 Omicron predominance merits evaluation, particularly given low coverage with updated COVID-19 vaccines. During December 19, 2021-October 29, 2023, the Overcoming COVID-19 Network evaluated vaccine effectiveness (VE) of ≥2 original monovalent COVID-19 mRNA vaccine doses against COVID-19-related hospitalization and critical illness among U.S. children and adolescents aged 5-18 years, using a case-control design. Too few children and adolescents received bivalent or updated monovalent vaccines to separately evaluate their effectiveness. Most case-patients (persons with a positive SARS-CoV-2 test result) were unvaccinated, despite the high frequency of reported underlying conditions associated with severe COVID-19. VE of the original monovalent vaccine against COVID-19-related hospitalizations was 52% (95% CI = 33%-66%) when the most recent dose was administered <120 days before hospitalization and 19% (95% CI = 2%-32%) if the interval was 120-364 days. VE of the original monovalent vaccine against COVID-19-related hospitalization was 31% (95% CI = 18%-43%) if the last dose was received any time within the previous year. VE against critical COVID-19-related illness, defined as receipt of noninvasive or invasive mechanical ventilation, vasoactive infusions, extracorporeal membrane oxygenation, and illness resulting in death, was 57% (95% CI = 21%-76%) when the most recent dose was received <120 days before hospitalization, 25% (95% CI = -9% to 49%) if it was received 120-364 days before hospitalization, and 38% (95% CI = 15%-55%) if the last dose was received any time within the previous year. VE was similar after excluding children and adolescents with documented immunocompromising conditions. Because of the low frequency of children who received updated COVID-19 vaccines and waning effectiveness of original monovalent doses, these data support CDC recommendations that all children and adolescents receive updated COVID-19 vaccines to protect against severe COVID-19.","PeriodicalId":18931,"journal":{"name":"Morbidity and Mortality Weekly Report","volume":" 39","pages":"330 - 338"},"PeriodicalIF":0.0000,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron–Associated Hospitalization in Children and Adolescents — United States, 2021–2023\",\"authors\":\"Laura D. Zambrano, Margaret M. Newhams, Regina M Simeone, Amanda B. Payne, Michael Wu, Amber O Orzel-Lockwood, N. Halasa, Jemima M Calixte, Pia S Pannaraj, K. Mongkolrattanothai, J. Boom, Leila C. Sahni, S. Kamidani, K. Chiotos, M. Cameron, A. Maddux, K. Irby, J. Schuster, E. Mack, Austin Biggs, B. Coates, Kelly N. Michelson, Katherine E Bline, Ryan A Nofziger, Hillary R Crandall, Charlotte V Hobbs, S. Gertz, Sabrina M. Heidemann, T. Bradford, Tracie C Walker, S. Schwartz, M. Staat, Samina S Bhumbra, J. Hume, Michele Kong, M. Stockwell, Thomas J Connors, M. Cullimore, H. Flori, Emily R Levy, N. Cvijanovich, M. Zinter, Mia Maamari, Cindy Bowens, Danielle M. Zerr, J. Guzman-Cottrill, Ivan Gonzalez, Angela P Campbell, Adrienne G Randolph, M. Murdock, Heather Kelley, Candice Colston, Ronald C. Sanders, Laura Miron, M. Yates, Ashlyn Madding, Alexa Dixon, Michael Henne, Kathleen Sun, Jazmin Baez Maidana, Natalie Triester, Jaycee Jumarang, Daniel Hakimi, Kennis-Grace Mrotek, Liria Muriscot Niell, Natasha Baig, E\",\"doi\":\"10.15585/mmwr.mm7315a2\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Pediatric COVID-19 vaccination is effective in preventing COVID-19-related hospitalization, but duration of protection of the original monovalent vaccine during SARS-CoV-2 Omicron predominance merits evaluation, particularly given low coverage with updated COVID-19 vaccines. During December 19, 2021-October 29, 2023, the Overcoming COVID-19 Network evaluated vaccine effectiveness (VE) of ≥2 original monovalent COVID-19 mRNA vaccine doses against COVID-19-related hospitalization and critical illness among U.S. children and adolescents aged 5-18 years, using a case-control design. Too few children and adolescents received bivalent or updated monovalent vaccines to separately evaluate their effectiveness. Most case-patients (persons with a positive SARS-CoV-2 test result) were unvaccinated, despite the high frequency of reported underlying conditions associated with severe COVID-19. VE of the original monovalent vaccine against COVID-19-related hospitalizations was 52% (95% CI = 33%-66%) when the most recent dose was administered <120 days before hospitalization and 19% (95% CI = 2%-32%) if the interval was 120-364 days. VE of the original monovalent vaccine against COVID-19-related hospitalization was 31% (95% CI = 18%-43%) if the last dose was received any time within the previous year. VE against critical COVID-19-related illness, defined as receipt of noninvasive or invasive mechanical ventilation, vasoactive infusions, extracorporeal membrane oxygenation, and illness resulting in death, was 57% (95% CI = 21%-76%) when the most recent dose was received <120 days before hospitalization, 25% (95% CI = -9% to 49%) if it was received 120-364 days before hospitalization, and 38% (95% CI = 15%-55%) if the last dose was received any time within the previous year. VE was similar after excluding children and adolescents with documented immunocompromising conditions. Because of the low frequency of children who received updated COVID-19 vaccines and waning effectiveness of original monovalent doses, these data support CDC recommendations that all children and adolescents receive updated COVID-19 vaccines to protect against severe COVID-19.\",\"PeriodicalId\":18931,\"journal\":{\"name\":\"Morbidity and Mortality Weekly Report\",\"volume\":\" 39\",\"pages\":\"330 - 338\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-04-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Morbidity and Mortality Weekly Report\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15585/mmwr.mm7315a2\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Morbidity and Mortality Weekly Report","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15585/mmwr.mm7315a2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
摘要
接种小儿 COVID-19 疫苗可有效预防与 COVID-19 相关的住院治疗，但在 SARS-CoV-2 Omicron 占主导地位期间，原始单价疫苗的保护持续时间值得评估，特别是考虑到更新的 COVID-19 疫苗覆盖率较低。2021 年 12 月 19 日至 2023 年 10 月 29 日期间，克服 COVID-19 网络采用病例对照设计，评估了≥2 剂原始单价 COVID-19 mRNA 疫苗对美国 5-18 岁儿童和青少年中 COVID-19 相关住院和危重病的疫苗有效性 (VE)。接种二价疫苗或更新单价疫苗的儿童和青少年人数太少，无法单独评估其效果。大多数病例患者（SARS-CoV-2 检测结果呈阳性者）都没有接种疫苗，尽管据报道与严重 COVID-19 相关的潜在疾病发生率很高。如果最近一剂疫苗在住院前<120天接种，则原始单价疫苗预防COVID-19相关住院的VE为52%（95% CI = 33%-66%）；如果间隔时间为120-364天，则VE为19%（95% CI = 2%-32%）。如果最后一剂疫苗是在前一年的任何时间接种的，那么原始单价疫苗预防COVID-19相关住院的VE为31%（95% CI = 18%-43%）。如果最近一剂疫苗是在住院前<120天接种的，则针对COVID-19相关重症（定义为接受无创或有创机械通气、血管活性输液、体外膜肺氧合以及导致死亡的疾病）的VE为57%（95% CI = 21%-76%）；如果最近一剂疫苗是在住院前120-364天接种的，则VE为25%（95% CI = -9%-49%）；如果最近一剂疫苗是在前一年的任何时间接种的，则VE为38%（95% CI = 15%-55% ）。在排除有免疫力低下记录的儿童和青少年后，VE 相似。由于儿童接种更新的 COVID-19 疫苗的频率较低，而且原始单价剂量的效力正在减弱，因此这些数据支持疾病预防控制中心的建议，即所有儿童和青少年都接种更新的 COVID-19 疫苗，以预防严重的 COVID-19。
Durability of Original Monovalent mRNA Vaccine Effectiveness Against COVID-19 Omicron–Associated Hospitalization in Children and Adolescents — United States, 2021–2023
Pediatric COVID-19 vaccination is effective in preventing COVID-19-related hospitalization, but duration of protection of the original monovalent vaccine during SARS-CoV-2 Omicron predominance merits evaluation, particularly given low coverage with updated COVID-19 vaccines. During December 19, 2021-October 29, 2023, the Overcoming COVID-19 Network evaluated vaccine effectiveness (VE) of ≥2 original monovalent COVID-19 mRNA vaccine doses against COVID-19-related hospitalization and critical illness among U.S. children and adolescents aged 5-18 years, using a case-control design. Too few children and adolescents received bivalent or updated monovalent vaccines to separately evaluate their effectiveness. Most case-patients (persons with a positive SARS-CoV-2 test result) were unvaccinated, despite the high frequency of reported underlying conditions associated with severe COVID-19. VE of the original monovalent vaccine against COVID-19-related hospitalizations was 52% (95% CI = 33%-66%) when the most recent dose was administered <120 days before hospitalization and 19% (95% CI = 2%-32%) if the interval was 120-364 days. VE of the original monovalent vaccine against COVID-19-related hospitalization was 31% (95% CI = 18%-43%) if the last dose was received any time within the previous year. VE against critical COVID-19-related illness, defined as receipt of noninvasive or invasive mechanical ventilation, vasoactive infusions, extracorporeal membrane oxygenation, and illness resulting in death, was 57% (95% CI = 21%-76%) when the most recent dose was received <120 days before hospitalization, 25% (95% CI = -9% to 49%) if it was received 120-364 days before hospitalization, and 38% (95% CI = 15%-55%) if the last dose was received any time within the previous year. VE was similar after excluding children and adolescents with documented immunocompromising conditions. Because of the low frequency of children who received updated COVID-19 vaccines and waning effectiveness of original monovalent doses, these data support CDC recommendations that all children and adolescents receive updated COVID-19 vaccines to protect against severe COVID-19.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
